Rare Disease Focus Farmington offers focused preclinical development consulting and nonclinical diligence for biotechs, pharma, and VC-backed portfolios, with experience on rare disease drug programs, presenting a niche for partners seeking specialized diligence and program management.

Flexible Capacity With a lean team model, Farmington can scale for client demands by partnering with subcontractors or a network of experts to handle larger projects, offering personalized service not feasible at larger CROs.

Expansion Potential Clients may look to extend beyond consulting to full GLP nonclinical studies and toxicology, pharmacology services; Farmington could position as a stepping stone to broader outsourcing partnerships, increasing project scope with existing biotech and pharma clients.

Regional Access Located in Cheshire, Connecticut, Farmington sits on the US East Coast where many biotech startups operate, enabling proximity-based collaborations and faster communication for preclinical engagements.

Niche Advantage In a landscape dominated by large CROs, Farmington’s boutique, specialized focus on preclinical diligence for niche programs like rare diseases can appeal to customers seeking high-touch, expert guidance and flexible engagement models.